The legal crisis facing the US CBD industry has deepened following confirmation that the Department of Justice’s landmark move to reschedule medical marijuana will do nothing to resolve the separate federal restriction on hemp-derived products scheduled to take effect in November 2026.
The DOJ released a final order on April 23, 2026, immediately rescheduling medical marijuana to Schedule III, coupled with an announcement of an expedited administrative process to consider the broader rescheduling of marijuana. While the decision was welcomed by the cannabis industry broadly, CBD manufacturers and hemp farmers quickly noted that the two issues operate on entirely different statutory tracks.
Rescheduling affects how the cannabis plant is classified under the Controlled Substances Act, but the hemp ban operates on a separate statutory track with its own distinct federal definition. The distinction matters enormously for the tens of thousands of businesses that sell non-intoxicating CBD products across the United States, many of which had hoped the rescheduling order might provide some protective effect.
In tandem with the April rescheduling, the Executive Branch reiterated its desire for Congress to amend the upcoming federal hemp language to preserve access to CBD products, signalling some hope for at least a partial preservation of the hemp industry going into the November deadline.
The hemp restrictions were enacted through Section 781 of the November 2025 continuing resolution. Because the ban was enacted through an appropriations bill rather than standalone legislation, it can technically be modified or overridden through several pathways, including a subsequent appropriations bill, the 2026 Farm Bill, standalone legislation such as the Mace Bill or Hemp Planting Predictability Act, or a comprehensive regulatory framework bill such as the HEMP Act.
The Hemp Planting Predictability Act, introduced in January 2026 by Representative Baird with bipartisan co-sponsors, would defer the effective date to November 2028. A Senate companion was introduced by Senators Klobuchar, Paul, and Merkley.
Senators Wyden and Merkley introduced the Cannabinoid Safety and Regulation Act in December 2025, which would replace the prohibition with a federal regulatory framework establishing THC limits of 5 milligrams per serving and 50 milligrams per container for edibles, with a federal minimum purchase age of 21, mandatory third-party testing, and standardised packaging requirements.
The Centers for Medicare and Medicaid Services is expected to begin a model allowing eligible Medicare beneficiaries to receive limited annual access, reported at up to $500, for hemp-derived CBD products. If implemented, the model could push the market toward conventional wellness positioning and away from products regulators view as intoxicating.
With multiple competing legislative proposals active and no single pathway commanding sufficient support, the November 2026 deadline continues to cast a shadow over investment decisions, supplier relationships, and retail listings across the CBD sector.